1. 441POT-1096: A first-in-class immunoactivating small molecule that targets the thioredoxin reductase/thioredoxin axis causes strong tumor growth inhibition by downregulating intratumoral tregs in a humanized TNBC-PDX model. (23rd October 2018) Authors: Orwar, O; Lowstedt, I; Andersson, K; Gannedahl, G; Willman, G; Davidsson, M; Stafford, W; Trkulja, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. B22 Does a peripheral immune response influence muscle pathology in Huntington's disease?. (29th August 2012) Authors: Magnusson-Lind, A; Davidsson, M; Silajdžić, E; Hansen, C; Tabrizi, SJ; Björkqvist, M Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 83(2012)Supplement 1 Page Start: A12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. INT-013 Developing a manipulation guideline for solid oral dosage forms to ease swallowing. (2nd March 2018) Authors: Bjerknes, KCF; Buan, L; Rise, T; Vukovic, M; Pedersen, E; Rognan, SE; Fjørkenstad, A; Lundstrøm, C; Norheim, AM; Brummenæs, HE; Davidsson, M; Bruun, LI Journal: European journal of hospital pharmacy Issue: Volume 25(2018)Supplement 1 Page Start: A250 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗